Should I buy or sell Xenon Pharmaceuticals stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XENE shares. View XENE analyst ratings or view top-rated stocks .

What is Xenon Pharmaceuticals' stock price target for 2024?

9 analysts have issued 12-month price objectives for Xenon Pharmaceuticals' shares. Their XENE share price targets range from $51.00 to $65.00. On average, they anticipate the company's share price to reach $59.44 in the next year. This suggests a possible upside of 43.3% from the stock's current price. View analysts price targets for XENE or view top-rated stocks among Wall Street analysts .

How have XENE shares performed in 2024?

Xenon Pharmaceuticals' stock was trading at $46.06 at the start of the year. Since then, XENE stock has decreased by 9.9% and is now trading at $41.48. View the best growth stocks for 2024 here .

When is Xenon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our XENE earnings forecast .

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) posted its earnings results on Thursday, February, 29th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.12. The business's revenue was up .0% on a year-over-year basis. During the same quarter last year, the business posted ($0.57) earnings per share.

What ETFs hold Xenon Pharmaceuticals' stock?

ETFs with the largest weight of Xenon Pharmaceuticals (NASDAQ:XENE) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) , Invesco Biotechnology & Genome ETF (PBE) , ALPS Medical Breakthroughs ETF (SBIO) , BNY Mellon Innovators ETF (BKIV) and First Trust Multi-Manager Small Cap Opportunities ETF (MMSC) . Harbor Health Care ETF (MEDI) .

What other stocks do shareholders of Xenon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE) , Dynavax Technologies (DVAX) , Corbus Pharmaceuticals (CRBP) , Nektar Therapeutics (NKTR) , TG Therapeutics (TGTX) , Viking Therapeutics (vktx) , Sangamo Therapeutics (SGMO) , Arbutus Biopharma (ABUS) , OPKO Health (OPK) and Spectrum Pharmaceuticals (SPPI) .

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include 17 Capital Partners LLC (0.00%). Insiders that own company stock include Christopher John Kenney , Dawn Svoronos , Frank A Holler , Gary Patou , Ian Mortimer , James R Empfield , Seggern Christopher Von , Sherrington Robin , Simon N Pimstone and Steven Gannon. View institutional ownership trends .

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:XENE

Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free XENE Stock Alerts

$41.52

+0.21 (+0.51%)

(As of 02:21 PM ET)

Compare

Today's Range: $41.00
▼
$42.03
50-Day Range: $41.30
▼
$50.04
52-Week Range: $27.99
▼
$50.99

Volume: 134,950 shs
Average Volume: 400,876 shs
Market Capitalization: $3.13 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $59.44

Get Xenon Pharmaceuticals alerts:

Xenon Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 43.3% Upside
$59.44 Price Target
Short Interest: Bearish
3.66% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.33
Based on 10 Articles This Week
Insider Trading: Selling Shares
$931,940 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.04) to ($3.51) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.55 out of 5 stars

Medical Sector

718th out of 930 stocks

Pharmaceutical Preparations Industry

325th out of 427 stocks

3.5

Analyst's Opinion

Consensus Rating
Xenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Xenon Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.66% of the outstanding shares of Xenon Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Xenon Pharmaceuticals has a short interest ratio ("days to cover") of 7.
Change versus previous month
Short interest in Xenon Pharmaceuticals has recently increased by 5.34%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Xenon Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Xenon Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for XENE.

1.9

News and Social Media Coverage

News Sentiment
Xenon Pharmaceuticals has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Xenon Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
Only 4 people have searched for XENE on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Xenon Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $931,940.00 in company stock.
Percentage Held by Insiders
Only 5.43% of the stock of Xenon Pharmaceuticals is held by insiders.
Percentage Held by Institutions
95.45% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($3.04) to ($3.51) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Xenon Pharmaceuticals is -15.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Xenon Pharmaceuticals is -15.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Xenon Pharmaceuticals has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

About Xenon Pharmaceuticals Stock (NASDAQ:XENE)

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

XENE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

XENE Stock News Headlines

April 16, 2024 | globenewswire.com

Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting

April 16, 2024 | americanbankingnews.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by Analysts

April 16, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 14, 2024 | americanbankingnews.com

Xenon Pharmaceuticals (NASDAQ:XENE) Given "Buy" Rating at Needham & Company LLC

April 11, 2024 | americanbankingnews.com

Cantor Fitzgerald Reaffirms Overweight Rating for Xenon Pharmaceuticals (NASDAQ:XENE)

April 10, 2024 | investing.com

Xenon Pharmaceuticals Inc (XENE)

April 10, 2024 | globenewswire.com

Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

April 4, 2024 | globenewswire.com

Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 16, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 21, 2024 | money.usnews.com

Xenon Pharmaceuticals Inc

March 19, 2024 | finance.yahoo.com

Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans

March 16, 2024 | finance.yahoo.com

XENE Apr 2024 47.500 put

March 12, 2024 | globenewswire.com

Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days

March 9, 2024 | finance.yahoo.com

Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...

March 5, 2024 | globenewswire.com

Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024

March 5, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progress

March 2, 2024 | seekingalpha.com

Xenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call Transcript

March 2, 2024 | finance.yahoo.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript

March 1, 2024 | finanznachrichten.de

Xenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 1, 2024 | markets.businessinsider.com

Buy Rating Justified by Xenon Pharmaceuticals’ Advanced Epilepsy Program and Growth Prospects in Neuroscience

February 29, 2024 | finance.yahoo.com

Xenon Pharmaceuticals Inc (XENE) Reports Full Year and Q4 2023 Financial Results

February 29, 2024 | globenewswire.com

Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

February 22, 2024 | globenewswire.com

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

February 21, 2024 | investorplace.com

3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition

February 8, 2024 | seekingalpha.com

Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'

February 7, 2024 | finance.yahoo.com

Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Trading At A 39% Discount?

January 23, 2024 | finance.yahoo.com

Here's Why You Should Add Xenon (XENE) to Your Portfolio Now

See More Headlines

Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:XENE
CUSIP: N/A
CIK: 1582313
Web: www.xenon-pharma.com
Phone: (604) 484-3300
Fax: 604-484-3450
Employees: 251
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $59.44
High Stock Price Target: $65.00
Low Stock Price Target: $51.00
Potential Upside/Downside: +43.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-182,390,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -25.18%
Return on Assets: -23.99%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 23.65
Quick Ratio: 23.65

Sales & Book Value

Annual Sales: $9.43 million
Price / Sales: 330.44
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $14.18 per share
Price / Book: 2.91

Miscellaneous

Outstanding Shares: 75,430,000
Free Float: 71,336,000
Market Cap: $3.12 billion
Optionable: Optionable
Beta: 1.15

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Ian C. Mortimer C.M.A. (Age 48)
CPA, M.B.A., President, CEO & Director
Comp: $973.76k
Ms. Sherry Aulin (Age 40)
Chief Financial Officer
Comp: $3.03M
Ms. Andrea DiFabio J.D. (Age 56)
Chief Legal Officer & Corporate Secretary
Comp: $200.51k
Dr. Christopher E. Von Seggern M.B.A. (Age 45)
M.P.H., M.P.H. M.B.A, Ph.D., Chief Commercial Officer
Comp: $618.07k
Dr. Christopher John Kenney M.D. (Age 53)
Chief Medical Officer
Comp: $684.22k
Ms. Shelley McCloskey B.A. (Age 64)
Executive Vice President of Human Resources
Dr. Robin P. Sherrington Ph.D. (Age 63)
Executive Vice President of Strategy & Innovation
Comp: $351.67k
Dr. James R. Empfield Ph.D. (Age 63)
Executive Vice President of Drug Discovery
Comp: $323.43k
Ms. Sheila M. Grant M.B.A.
M.Sc., MBA, Executive Vice President of R&D Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XENE Stock Analysis - Frequently Asked Questions

Should I buy or sell Xenon Pharmaceuticals stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XENE shares.
View XENE analyst ratings or view top-rated stocks.
What is Xenon Pharmaceuticals' stock price target for 2024?: 9 analysts have issued 12-month price objectives for Xenon Pharmaceuticals' shares. Their XENE share price targets range from $51.00 to $65.00. On average, they anticipate the company's share price to reach $59.44 in the next year. This suggests a possible upside of 43.3% from the stock's current price.
View analysts price targets for XENE or view top-rated stocks among Wall Street analysts.
How have XENE shares performed in 2024?: Xenon Pharmaceuticals' stock was trading at $46.06 at the start of the year. Since then, XENE stock has decreased by 9.9% and is now trading at $41.48.
View the best growth stocks for 2024 here.
When is Xenon Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our XENE earnings forecast.
How were Xenon Pharmaceuticals' earnings last quarter?: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) posted its earnings results on Thursday, February, 29th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.12. The business's revenue was up .0% on a year-over-year basis. During the same quarter last year, the business posted ($0.57) earnings per share.

What ETFs hold Xenon Pharmaceuticals' stock?: ETFs with the largest weight of Xenon Pharmaceuticals (NASDAQ:XENE) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO), BNY Mellon Innovators ETF (BKIV) and First Trust Multi-Manager Small Cap Opportunities ETF (MMSC).Harbor Health Care ETF (MEDI).
What other stocks do shareholders of Xenon Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Viking Therapeutics (vktx), Sangamo Therapeutics (SGMO), Arbutus Biopharma (ABUS), OPKO Health (OPK) and Spectrum Pharmaceuticals (SPPI).
Who are Xenon Pharmaceuticals' major shareholders?: Xenon Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include 17 Capital Partners LLC (0.00%). Insiders that own company stock include Christopher John Kenney, Dawn Svoronos, Frank A Holler, Gary Patou, Ian Mortimer, James R Empfield, Seggern Christopher Von, Sherrington Robin, Simon N Pimstone and Steven Gannon.
View institutional ownership trends.
How do I buy shares of Xenon Pharmaceuticals?: Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XENE) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial